Trials / Terminated
TerminatedNCT03990077
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
A Phase I , Single Arm, Dose Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Shanghai Kechow Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, open label, dose escalation study to evaluate tolerability, safety , pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and Docetaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL-085 | HL-085 ( Capsule) is one MEK inhibitor. |
| DRUG | Docetaxel | Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression. |
Timeline
- Start date
- 2020-05-21
- Primary completion
- 2021-07-20
- Completion
- 2021-07-20
- First posted
- 2019-06-18
- Last updated
- 2021-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03990077. Inclusion in this directory is not an endorsement.